FDA declares semaglutide shortage over, spelling end to compounded GLP-1 market, for now
The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and Wegovy, is no longer in short supply. | The demand for weight loss drugs is not slowing down,
Hims & Hers Health put out a jaw dropping commercial. Now, Hims stock is just dropping, as its semaglutide business faces a ...
Semaglutide — the type 2 diabetes and weight loss medication sold under the brand names Ozempic and Wegovy — can expire. If ...
The FDA recently removed semaglutide from its drug shortage list, which has not been considered commercially available since ...
Lilly expands its Zepbound vial offering, as HIMS pulls back on semaglutide, and other biotech news in today's Readout newsletter.
Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...
Scientists in China have found a new potential drug target for weight loss. Blocking a protein called CD44 has been shown to ...
RAs are transforming obesity treatment, demonstrating substantial weight loss and metabolic improvements with lifestyle ...
Semaglutide use in patients with Type 2 diabetes was associated with reduced postoperative complications after 90 days, according to a study in the March 2025 i ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback